1. Brazil Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Raia Drogasil S.A.

Raia Drogasil S.A.

RADLY
Raia Drogasil S.A.US flagOther OTC
3.85
USD
-0.08
- -
6.73BMarket Cap
Raia Drogasil S.A.
RADLY
(Other OTC)

Recent

price

3.85

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
2.1
2.92
3.07
3.56
4.21
5.09
6.44
7.56
8.47
10.05
11.47
13.79
17.3
20.43
23.11
26.87
20.34
Revenue per Share
0.09
0.07
0.06
0.06
0.13
0.19
0.26
0.29
0.29
0.44
0.28
0.43
0.59
0.63
0.71
0.79
0.54
Basic EPS, GAAP
-0.05
-0.06
-0.09
0.04
0.04
0.07
0.04
-0.01
-0.01
0.26
0.46
0.4
-0.21
-0.21
0.37
0.06
0.05
Free Cash Flow per Basic Share
0.03
0.04
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.6
2.35
1.29
1.33
1.41
1.51
1.66
1.84
2
2.3
2.49
2.68
3.06
3.41
3.68
4.11
4.17
Book Value per Share
0.54
1.15
0.62
0.67
0.76
0.84
0.99
1.16
1.32
1.59
1.77
1.83
2.06
2.31
2.52
2.96
3
Tangible Book Value per Share
953
935
1,752
1,752
1,747
1,747
1,749
1,749
1,747
1,747
1,749
1,750
1,681
1,663
1,682
1,647
1,658
Basic Weighted Avg Shares
2,005
2,729
5,381
6,233
7,351
8,898
11,257
13,213
14,801
17,566
20,067
24,127
29,067
33,974
38,872
44,250
33,734
Sales/Revenue/Turnover
5.6
2.92
2.99
2.4
4.66
5.63
6.27
6
5.18
5.07
4.46
5.69
6.42
5.75
6.1
5.99
6.1
Operating Margin (%)
31
56
124
159
188
228
274
338
414
1,041
1,177
1,327
700
798
912
1,049
623
Depreciation Expense
89
69
105
101
221
340
448
511
502
772
484
752
996
1,055
1,200
1,297
888
Net Income, GAAP
26.33
24.68
33.67
27.55
26.75
22.05
24.19
25.33
20.28
- -
19.6
22.6
14.94
10.65
14.63
10.21
11.06
Effective Tax Rate (%)
4.44
2.52
1.95
1.62
3.01
3.82
3.98
3.87
3.39
4.4
2.41
3.12
3.43
3.11
3.09
2.93
2.63
Profit Margin (%)
379
835
831
884
969
1,037
1,243
1,434
1,616
1,678
2,219
1,823
3,210
3,482
3,509
4,711
4,116
Working Capital
28
112
131
161
184
188
281
415
570
3,516
4,050
3,865
5,112
5,604
6,130
7,305
7,202
LT Debt
599
2,201
2,265
2,327
2,457
2,657
2,936
3,250
3,535
4,076
4,426
4,719
5,403
6,028
6,447
7,336
7,291
Total Equity
10.92
3.68
4.33
4.22
9.27
13.51
16.6
15.93
14.46
- -
7.94
10.8
14.64
13.93
14.5
15.34
11.51
Return on Invested Capital (%)
12.54
4.78
4.81
4.56
9.02
12.91
15.48
15.54
13.16
- -
7.84
10.14
13.61
13.7
13.81
14.84
10.85
Return on Capital (%)
17.62
4.91
4.7
4.4
9.26
13.37
16.15
16.67
14.95
20.53
11.55
16.63
19.89
18.68
19.37
18.86
12.73
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1,529
1,443
1,391
LT Borrowings
3,360
3,236
3,087
LT Finance Leases
3,945
4,015
4,115
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,782
1,749
1,749
Market Capitalization
45,509
41,939
31,289

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
14,904
15,357
14,252
Cash, Cash Equivalents & STI
529
538
653
Accounts Receivable, Net
3,401
2,835
3,096
Inventories
9,576
8,440
8,334
Total Current Liabilities
10,194
10,456
10,136
Payables & Accruals
- -
- -
- -
ST Debt
1,529
1,443
1,391
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.73%
10.68%
13.79%
Free Cash Flow
-294.33%
-106.26%
-83.07%
Net Income, GAAP
17.59%
23.08%
8.08%
Sales/Revenue/Turnover
17.47%
17.17%
13.84%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
9,100
9,687
9,989
10,088
38,872
2025
9,273
10,075
- -
12,103
44,250
2026
10,569
11,062
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.11
0.19
0.2
- -
0.71
2025
0.1
0.23
- -
- -
0.79
2026
0.1
0.26
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Renascience Inc. (4889.T)
SCYNEXIS, Inc. (SCYX)
Shijiazhuang Yiling Pharmaceutical Co., Ltd. (002603.SZ)
Phaarmasia Limited (PHRMASI.BO)
Doseology Sciences Inc. (DOSEF)
Kangmei Pharmaceutical Co., Ltd. (600518.SS)
Business
Raia Drogasil S.A. (RADLY) operates as Brazil's largest pharmacy chain, engaging in the retail sale of medicines including branded, generic, over-the-counter, and specialty drugs; perfumery; personal hygiene and beauty products; cosmetics; and dermocosmetics, supplemented by health and beauty aids, household items, and private label brands. The company sells through over 3,000 Raia- and Drogasil-branded stores across all 27 Brazilian states, supported by 14 distribution centers, telesales, call centers, mobile apps, and e-commerce platforms that accounted for 15% of 2023 retail revenues; it also functions as a pharmacy benefit manager offering prenegotiated medical purchases and provides ancillary services via subsidiaries and investments such as Manipulaê for on-site compounded medications, Vitat for comprehensive health promotion, Labi Exames for laboratory analysis and vaccines, and Amplimed for electronic medical records. Founded in 2011 through the merger of Droga Raia (established 1905) and Drogasil (established 1935), Raia Drogasil maintains headquarters in São Paulo, Brazil, at Av. Corifeu de Azevedo Marques, 3097, Butantã, and employs approximately 59,000 people while serving urban and rural customers nationwide. Recent developments include a leadership transition in early 2025 with Renato Raduan assuming the presidency from Marcilio Pousada, who became board president; ongoing store expansion with 88 new pharmacies opened in Q3 2025 to boost market share; a 62% surge in digital sales during the same period; and accelerated growth from GLP-1 medication sales following the May 2025 launch of Mounjaro in Brazil, prompting UBS to upgrade its stock rating to Buy in October 2025.

Company News

Company News APIChatGPT

  • seekingalpha.com

    Raia Drogasil S.A. (RADLY) Q2 2026 Earnings Call Transcript

  • seekingalpha.com

    Raia Drogasil S.A. (RADLY) Q1 2026 Earnings Call Transcript

  • defenseworld.net

    Short Interest in Raia Drogasil S.A. (OTCMKTS:RADLY) Increases By 138.8%

  • seekingalpha.com

    Raia Drogasil S.A. (RADLY) Q4 2025 Earnings Call Transcript

  • defenseworld.net

    Raia Drogasil S.A. (OTCMKTS:RADLY) Short Interest Update

  • seekingalpha.com

    Raia Drogasil S.A. (RADLY) Q3 2025 Earnings Call Transcript

  • seekingalpha.com

    Invesco International Small-Mid Company Fund Q3 2025 Top Contributors And Detractors

  • seekingalpha.com

    Raia Drogasil: Valuation Burn Now, Healthy Gains Later

  • investorplace.com

    What's Hot, What's Not: China Stocks Are Out. Top Picks From 3 Other Countries

  • investorplace.com

    3 Stocks to Ride the Latin America Market Boom in 2024

  • investorplace.com

    The 3 Best South American Stocks to Buy in 2023